Althugh the terms were greatly improved vs. the failed Tullow berger, top shareholders have spoken out against the sale to NewMed and argue that the deal undervalues CNE's assets.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.